
Cognition Therapeutics Reports Promising Findings in Phase 2 Trial of CT1812 for Dementia with Lewy Bodies
Exciting Developments in Neurodegenerative Disorder Treatment Improvements Across Measures of Behavior, Function, Cognition, and Movement A recent announcement from Cognition Therapeutics, Inc. has brought hope to patients suffering from dementia with Lewy bodies (DLB). The topline results from the Phase 2 ‘SHIMMER’ study show that CT1812, a drug developed by Cognition Therapeutics, has shown promising…